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Abstract
Background: Activation of proto-oncogenes by DNA amplification is an important mechanism in
the development and maintenance of cancer cells. Until recently, identification of the targeted
genes relied on labour intensive and time consuming positional cloning methods. In this study, we
outline a straightforward and efficient strategy for fast and comprehensive cloning of amplified and
overexpressed genes.
Results: As a proof of principle, we analyzed neuroblastoma cell line IMR-32, with at least two
amplification sites along the short arm of chromosome 2. In a first step, overexpressed cDNA
clones were isolated using a PCR based subtractive cloning method. Subsequent deposition of these
clones on a custom microarray and hybridization with IMR-32 DNA, resulted in the identification
of clones that were overexpressed due to gene amplification. Using this approach, amplification of
all previously reported amplified genes in this cell line was detected. Furthermore, four additional
clones were found to be amplified, including the TEM8 gene on 2p13.3, two anonymous transcripts,
and a fusion transcript, resulting from 2p13.3 and 2p24.3 fused sequences.
Conclusions: The combinatorial strategy of subtractive cDNA cloning and array CGH analysis
allows comprehensive amplicon dissection, which opens perspectives for improved identification
of hitherto unknown targeted oncogenes in cancer cells.
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Human cancers frequently manifest amplification of large
stretches of DNA, cytogenetically detectable as homoge-
neously staining regions (HSR) or double minute chro-
matin bodies (dmin). DNA amplification is considered to
be a consequence of the intrinsic genomic instability of
cancer cells, and it is presumed that overexpression of a
single or few amplified genes confers a selective advantage
on these HSR or dmin bearing clones. Consequently, acti-
vation of proto-oncogenes by amplification is thought to
play an important role in the development and mainte-
nance of many human solid tumours [1-3]. Detection of
amplification of many different chromosomal regions in
various tumour types has lead to the identification of the
targeted oncogenes and greatly contributed to our current
understanding of the genetic basis of cancer. Furthermore,
amplified genes often act as markers of tumour behaviour,
drug response, patient outcome, and may represent tar-
gets for future molecular cancer therapy.
In the past, various strategies have been used for the detec-
tion of amplified chromosomal regions and DNA
sequences in cancer. Comparative genomic hybridization
(CGH) [4] has been particularly useful for detection of
amplified sequences and assignment of the chromosomal
position [5]. This approach allows whole genome screen-
ing for chromosomal imbalances up to 5–10 Mb and gene
amplification of sufficiently large amplicons and/or
highly overrepresented regions. Due to this limited reso-
lution, a time consuming mapping is required following
amplicon identification in order to pinpoint the putative
target genes. Recently, two methods were introduced that
allow mapping of the genomic content of amplicons with
a 10–100 fold increased resolution. Array CGH employs
arrayed fragments of genomic DNA clones (with partial or
complete sequence information) instead of metaphase
chromosomes [6,7]. Digital karyotyping is a SAGE (serial
analysis of gene expression) based method to enumerate
genomic DNA tags [8]. This method allows identification
of specific amplifications and deletions that were not pre-
viously detected by conventional CGH or other methods.
An important limitation of both methods is the inability
to directly identify the overexpressed genes that are tar-
geted by the amplification. This limitation was overcome
by another variant on the classic CGH approach in which
the normal metaphase chromosomes were replaced by a
large number of microarrayed cDNA clones [9]. This
approach has the advantage that losses and gains are
mapped by their gene position rather than chromosomal
band (as with conventional CGH) or genomic position
(as with array CGH and digital karyotyping). The analysis
immediately provides a list of candidate genes that occur
within the region of interest. Another advantage is the
ability to perform expression profiling on the same slides
using the cDNA microarray approach, which enables the
investigator to correlate copy number and gene expres-
sion, in order to identify candidate oncogenes that are
both amplified and overexpressed. Moreover, the small
size and large number of the arrayed cDNA clones provide
a higher resolution in contrast to current PAC and BAC
arrays for which the resolution is limited because of the
relatively large size of the clones (120–200 kb). Two lim-
itations of the cDNA array CGH approach are the con-
fined analysis of genes that are present on the array and
the analytical challenges in terms of sensitivity by the
complexity of the probe and the small sizes of the arrayed
target cDNAs (0.5–2 kb) (signal intensities in genomic
hybridizations being proportional to the length of the tar-
get DNA).
In this paper, we propose a fast and straightforward
approach to identify overexpressed genes in amplified
regions, enabling direct identification of the relevant tar-
geted oncogene(s). The approach is based on the above-
mentioned cDNA array CGH method, but includes a pre-
ceding selection of differentially expressed genes. In a first
step, subtractive cDNA cloning is performed on an ampli-
fied tumour sample to isolate cDNA clones that are over-
expressed. Subsequent CGH analysis on a cDNA
microarray containing the subtracted clones allows detec-
tion of differentially expressed genes which are amplified
at the DNA level. As a proof of principle, neuroblastoma
cell line IMR-32 with at least two amplification sites along
the short arm of chromosome 2 (including the MYCN
locus) was used as a model system [10,11].
In this study, the combinatorial power and efficacy of sub-
tractive cDNA cloning and high-throughput DNA copy
number determination using array CGH was demon-
strated for identification of amplified and overexpressed
genes. In addition to those genes which were already
known to be amplified and overexpressed in IMR-32, we
also detected hitherto unknown genes, which were not
previously described to be amplified in neuroblastoma.
Results
Identification of differentially expressed genes by 
suppression subtractive hybridisation (SSH)
In a first step, overexpressed genes in neuroblastoma cell
line IMR-32 were isolated (of which some have increased
expression due to amplification) through a PCR select
cDNA subtraction with IMR-32 as tester and SK-N-SH as
driver (the latter being a neuroblastoma cell line without
DNA amplification [12]). This yielded a cDNA library of
960 clones. By comparing the unsubtracted and sub-
tracted cDNA library for the abundance of an internal con-
trol gene GAPD, the enrichment was estimated to be 100
fold. Upon hybridization of the subtracted and reverse
subtracted probe on nylon filters containing all subtracted
clones (i.e. differential screening according to thePage 2 of 14
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expressed genes) could be identified, resulting in the
retention of 281 IMR-32 overexpressed clones. After
sequencing, alignment, EST contig building and UniGene
database search, a non-redundant list was obtained con-
taining 126 known genes, 22 UniGene clusters, and 10
anonymous ESTs. For each unique gene, transcript or EST
contig, at least one representative clone was selected for
re-arraying, insert amplification and spotting on a custom
microarray.
CGH on cDNA microarray and characterization of the 
clones
In order to determine which of the overexpressed cDNA
clones were amplified in IMR-32, array CGH analysis was
performed on a custom cDNA microarray using DNA of
IMR-32 as test probe and DNA of a normal male lym-
phoblastoid cell line as normal control probe. All clones
that were found to be amplified, were located on one of
the two known amplified regions on the short arm of
chromosome 2 (2p13-14 and 2p24) (Figures 1 and 2). In
addition to the 3 known genes on 2p24 that are frequently
co-amplified in neuroblastoma (i.e. MYCN, DDX1 and
NAG), ten other partial cDNA clones on the microarray
were shown to be amplified in cell line IMR-32. One clone
(g6f6) was part of the MEIS1 homeobox gene (2p14) that
was recently shown also to be amplified in IMR-32
[13,14]. Two other clones (g1h7 and g8f10) belonged to
the TEM8 gene on 2p13.3. A fourth clone (g4d5) is
located between the MEIS1 and the TEM8 gene and is part
of an as yet not characterized gene. RT-PCR analysis
revealed that this clone is not part of the neighbouring
(not yet fully annotated) ETAA16 gene. No homology was
found for g4d5 with other EST sequences or known genes.
Another clone (g10d12) is located 500 kb telomeric to
NAG and also displayed no homology to any known
sequence. Two other transcripts (g9d9 and g10e3) are
probably part of the NSE1 gene as demonstrated by align-
ment of the clones to NSE1 transcript variants (Figure 2)
and RT-PCR assays using a forward primer in the sub-
tracted clone and a reverse primer in the NSE1 gene. Two
clones (g1c2, g6d4) were located in the large 150 kb
intron of the 4.5 kb NAG sequence reported by Wimmer
et al. [15] (acc. no. AF056195) between exon 4 and 5.
BLAST analysis of the human EST database with exon 4
and 5 of the NAG gene as a query sequence failed to iden-
tify an EST clone that contained both exons. Furthermore,
RT-PCR with a forward primer in exon 4 and a reverse
primer in exon 7 failed to yield the expected band of 341
bp in IMR-32 and SK-N-SH. In contrast, a sharp and single
band of approximately 3.5 kb was amplified. Further-
more, Northern blot analysis estimated the NAG tran-
script size to be approximately 2.5 kb longer compared to
the published sequence (data not shown). These data fur-
ther support the recent observation that the published
NAG gene (acc. no. AF056195) is misannotated and
should contain 21 more exons between former exon 4
and 5 [16]. Hence, clones g1c2 and g6d4 (present on our
cDNA array) and clone g3e7 are in fact part of the newly
annotated NAG gene (acc. no. AF388385).
The tenth amplified clone (g2h10a) is of particular inter-
est because one part of the sequence aligns to the TEM8
gene on 2p13.3 and the other part aligns to a sequence in
band 2p24.3 (Figure 2). The fusion nature of this clone
was confirmed by RT-PCR on cell line IMR-32 using a
primer in the first part of the transcript on 2p13.3 and a
primer in the other part of the transcript on 2p24.3. Clon-
ing and sequencing of the PCR product revealed that IMR-
32 contains at least two different splice variants of the
fusion transcript, i.e. g2h10b (acc. no. CD664535) and
g2h10c (acc. no. CF384614) (splice variants are detected
in the part that aligns to 2p24.3). Most splicing sites are
surrounded by consensus splice site sequences (data not
shown).
Confirmation of amplification status
Real-time quantitative PCR on IMR-32 was performed in
order to validate the amplification status of all sequences
that were catalogued as amplified by array CGH analysis:
five genes that were previously reported to be amplified in
IMR-32 (MYCN, DDX1, NAG, NSE1 and MEIS1), one
newly amplified gene (TEM8), 2 anonymous expressed
sequences (g10d12 and g4d5) and 1 fusion transcript.
Amplification of all these genes and clones was confirmed
in IMR-32 (Table 2).
Using FISH analysis, it was demonstrated that the MYCN,
DDX1, NAG, MEIS1, NSE1 and TEM8 genes and the
g10d12 clone are present as multiple copies on all 3
known HSRs in IMR-32 (Figure 3). This suggests that the
3 HSRs originate from the same complex amplicon.
To verify whether the subtracted clones that were shown
to be amplified are indeed overexpressed at the mRNA
level in IMR-32, real-time quantitative RT-PCR was per-
formed and demonstrated that all genes were highly over-
expressed (range 101–104 fold overexpression) (Table 2).
The fusion transcript was only expressed in cell line IMR-
32.
Three genes were shown to be amplified in the 2p13.3-14
amplicon (of which only MEIS1 was previously reported).
To our surprise, more known genes are located between
amplified clone g4d5 and TEM8, but those were not
present in our subtracted cDNA library. To test whether
our approach failed to identify these genes or whether
these genes were indeed not amplified in IMR-32, we ran-
domly selected 3 genes (PPP3R1, PLEK and BMP10) andPage 3 of 14
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IMR-32. Neither amplification nor overexpression could
be detected for these genes, demonstrating that the
2p13.3-14 amplicon in IMR-32 is complex and
discontinuous.
A recent study reported that the DNMT3A gene on chro-
mosome band 2p23.3 is amplified in IMR-32 and is prob-
ably part of a third amplicon on 2p [17]. As our approach
did not identify this gene, we decided to evaluate the
DNMT3A gene copy number and expression level with
real-time quantitative PCR. Neither amplification nor
overexpression could be detected in cell line IMR-32.
Extended gene copy number and mRNA expression 
analysis of the novel amplified genes in a panel of 
neuroblastoma cell lines
Real-time quantitative PCR was performed in order to
analyse the mRNA expression level and gene copy number
of novel amplified genes TEM8, g10d12, g10e3, and g4d5,
and already known amplified genes MYCN, DDX1, NAG
and MEIS1 in 30 NB cell lines and 9 normal human tissue
samples (Table 3 and Figure 4). These analyses showed
that g10e3 and g4d5 were only amplified and overex-
pressed in cell line IMR-32. Clone g10d12 was also found
to be amplified and overexpressed in cell line SJNB-6.
Subsequent gene copy number determination of g10d12
in primary tumour samples indicated a co-amplification
frequency with MYCN of 12 % (9/75 tested MYCN ampli-
Array CGH based haploid copy number of SSH clones mapping on chromosome 2Figure 1
Array CGH based haploid copy number of SSH clones mapping on chromosome 2: Base position of the SSH clones 
on chromosome 2 (with exception of fusion transcript clone g2h10) was determined according to the human genome browser 
at UCSC (April 2003 freeze [33]). Two clear amplification sites along the short arm emerge. Insert: detail of the array CGH 
(IMR-32 in red and control DNA in green), amplified clones are indicated.
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Genomic position of known genes and 2p amplified SSH clones: These results were obtained by a human BLAT 
search (UCSC genome browser, April 2003 freeze [33]) (clones that were present on the microarray are marked in blue; Ref-
Seq genes are marked in red and the initially misannotated gene NAG in grey). A: amplicon on chromosome band 2q13.3-14; B 
and C: amplicon on chromosome band 2p24.3 (acc. no. of SSH clone sequences between brackets).
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amplification pattern for TEM8 resembles that of MEIS1
([13] and this study): high expression in a number of cell
lines, independent of DNA amplification.
Discussion
In this study, we demonstrate that subtractive cDNA clon-
ing followed by CGH on cDNA microarrays containing
the subtracted clones is a powerful strategy for rapid and
efficient isolation of amplified genes that are overex-
Table 1: Oligonucleotide sequences for real-time PCR based DNA copy number determination (GCN) and gene expression analysis 
(GXP): Primer sequences for known genes are submitted to RTPrimerDB [37,38]. Proper DNase treatment (see Methods) allows the 
use of intra-exonic primer pairs for both DNA and RNA profiling (F: forward primer; R: reverse primer).
APPLICATION GENE/CLONE PRIMER SEQUENCES (5' > 3')
GCN MYCN RTPrimerDB ID 11
GXP MYCN RTPrimerDB ID 180
GCN DDX1 RTPrimerDB ID 12
GXP DDX1 RTPrimerDB ID 93
GCN NAG RTPrimerDB ID 13
GXP NAG RTPrimerDB ID 114
GCN + GXP g10e3 F CTTTTCCTAAGAGCAAGGAAACAGA
R CTGTTATTTAAAGAAACCAGCATTCACT
GCN + GXP g9d9 F CTTTGGCCAGTTCCACAGTTC
R CACACCCAGCCTTAAGTTTTTGA
GCN + GXP NSE1 RTPrimerDB ID 715
GCN + GXP g10d12 F ACCTTCCATCCACACCTATGCT
R TTTCATTCAGTTCAGTCTTCATCGA
GCN + GXP DNMT3A RTPrimerDB ID 713
GCN + GXP TEM8 RTPrimerDB ID 712
GCN + GXP BMP10 RTPrimerDB ID 717
GCN + GXP PLEK RTPrimerDB ID 716
GCN + GXP PPP3R1 RTPrimerDB ID 718
GCN + GXP g4d5 F AGATGCCCATTTCATCTCTCTTG
R TGCTACAGGTCTTGCATTATCAAAC
GCN + GXP ETAA16 F RTPrimerDB ID 714
GCN + GXP MEIS1 RTPrimerDB ID 690
GCN + GXP g2h10 F TTCCTGATGCCCACAAAGTTTA
R ACACAAACTCTGAAAGCCAACTAATTT
Table 2: Haploid DNA copy number in IMR-32 and SK-N-SH compared to a normal human control sample and fold expression 
difference between IMR-32 and SK-N-SH (tester vs. driver): Real-time quantitative PCR based determination of gene copy number and 
fold-expression of 5 previously reported amplified genes (MYCN, DDX1, NAG, NSE1, MEIS1) and 6 other amplified 2p clones (rounded 
mean of 2 measurements) (*primers designed in 2p24.3; **no expression in SK-S-SH).
GENE CLONE ACCESSION 
NUMBER
LOCATION HAPLOID COPY 
NUMBER IN IMR-32
HAPLOID COPY 
NUMBER IN SK-N-SH
FOLD OVER-
EXPRESSION
MYCN NM_005378 2p24.3 53 1.26 513
DDX1 NM_004939 2p24.3 42 1.28 40
NAG AF388385 2p24.3 41 1.31 37
NSE1 g10e3 CD664581 2p24.3 70 1.27 280
g9d9 CD664576 44 1.05 193
NM_145175 34 0.93 236
- g10d12 CD664582 2p24.3 27 1.17 1616
TEM8 g1h7 CD664531 2p13.3 26 1.02 8
- g4d5 CD664538 2p14 30 1.04 1819
MEIS1 g6f6 CD664530 2p14 42 1.27 10
- g2h10a CD664534 2p24.3* 42 1.07 **Page 6 of 14
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oma cell line IMR-32 which contains at least two distinct
amplification sites on the short arm of chromosome 2
[10,11].
Upon subtractive cDNA cloning and array CGH analysis,
fifteen partial cDNA clones located on these sites on 2p
were found to be amplified in IMR-32, representing 9 dif-
ferent transcripts. Five of these constitute genes that were
previously reported to be amplified in IMR-32 (Table 4),
i.e. MYCN [18], DDX1 [19], NAG [15] and NSE1 [17] on
chromosome band 2p24, and MEIS1 [13,14] on 2p14,
demonstrating the validity and success of our approach.
We not only confirmed NAG amplification, but also iso-
lated two partial cDNA clones located within a large
intron of the NAG gene. Subsequent analyses demon-
strated that these clones are part of the NAG gene that was
initially misannotated and should in fact contain 21 addi-
tional exons, as recently confirmed in another study [16].
We also identified 4 newly amplified transcripts, includ-
ing the tumour endothelial marker gene TEM8 (2 partial
cDNA clones), encoding a protein highly expressed in
tumour endothelial cells but not in normal endothelial
cells [20]. Two other transcripts show no homology to any
known sequence. The detailed characterization of these
anonymous transcripts was beyond the scope of this
study.
Our amplicon dissection strategy clearly provides a com-
prehensive view on the gene content and complex struc-
ture of the HSRs (homogeneously staining regions)
present in cell line IMR-32. All three HSRs appear to con-
tain the same genes as visualized in a series of FISH map-
pings, and presumably arise from a single non-synthenic
Table 3: Relative expression levels obtained by real-time quantitative RT-PCR: Quantitative RT-PCR results in 30 NB cell lines and 9 
normal human tissue samples (- : not tested; samples with gene amplification are marked in bold-italics).
Sample MYCN TEM8 DDX1 NAG g10e3 g10d12 g4d5 MEIS1
CHP134 1.79E+00 2.40E-01 5.13E+00 2.13E+00 1.21E-01 1.60E-03 4.08E-03 2.39E+00
CHP901 9.72E-01 1.04E-01 1.71E-02 8.94E-02 9.57E-02 6.24E-03 0.00E+00 4.28E-01
CLB-GA 5.35E-02 3.08E-01 1.10E-01 4.19E-01 2.08E-01 2.69E-02 9.98E-03 5.42E-01
GI-ME-N 9.37E-05 4.53E-01 4.95E-02 2.09E-01 2.71E-01 9.83E-03 0.00E+00 1.27E-01
IMR-32 2.00E+00 1.48E+01 2.94E+00 8.78E+00 2.84E+01 1.81E+01 4.06E+01 3.66E+00
LA-N-1 2.31E+00 4.21E-01 4.64E+00 1.39E-01 1.06E-01 2.84E-03 5.01E-02 3.09E-01
LA-N-5 1.16E+00 3.17E-01 2.15E+00 3.95E-01 1.38E-01 2.56E-02 0.00E+00 5.62E-01
LA-N-6 6.93E-03 1.71E-01 1.09E-01 4.72E-01 8.31E-02 2.94E-02 1.99E-02 1.53E-01
N206 2.79E+00 2.22E-01 1.49E-01 4.91E-01 7.35E-01 1.09E-01 1.21E-01 6.48E-01
NBL-S 1.32E-01 3.67E-01 7.35E-02 3.63E-01 4.96E-01 5.28E-02 7.37E-02 6.96E-01
NGP 5.86E+00 1.14E-01 1.25E-01 1.03E+00 2.91E-01 1.10E-02 0.00E+00 1.85E+00
NLF 3.99E-01 1.21E+00 2.91E+00 3.10E-01 2.20E-02 1.38E-02 0.00E+00 2.38E+00
NMB 1.65E+00 8.94E-01 9.47E-02 2.78E-01 5.41E-01 2.15E-02 3.00E-02 1.23E+00
SJNB-1 5.14E-02 4.14E-01 6.76E-02 1.98E-01 3.83E-01 3.26E-02 5.34E-02 3.16E-01
SJNB-10 2.16E+00 2.56E-01 4.89E-02 2.63E-01 1.16E-01 1.92E-02 9.66E-02 1.94E-01
SJNB-12 4.70E-06 3.11E-01 8.89E-02 2.46E-01 3.96E-01 1.60E-02 5.48E-03 1.14E+00
SJNB-6 1.44E+00 2.19E-01 4.61E-02 4.91E-01 4.12E-01 1.44E+00 4.37E-02 7.26E-01
SJNB-8 2.99E+00 6.71E-01 6.26E+00 3.40E-01 3.57E-01 0.00E+00 5.35E-02 3.47E+00
SK-N-AS 2.39E-03 7.89E-01 6.05E-02 1.76E-01 4.54E-03 7.46E-03 2.39E-01 2.63E+00
SK-N-BE 5.31E-01 7.13E-02 8.12E-02 3.30E-01 1.50E-01 3.60E-02 7.36E-02 1.49E-01
SK-N-FI 9.22E-02 8.44E-01 3.69E-02 1.24E-01 7.22E-03 0.00E+00 3.18E-02 2.73E-01
SK-N-SH 3.90E-03 1.88E+00 7.43E-02 2.36E-01 1.01E-01 1.12E-02 2.23E-02 3.78E-01
SMS-KAN 4.59E+00 3.10E-01 5.93E-02 1.55E-01 1.39E-01 6.69E-03 3.03E-02 2.41E+00
SMS-KCNR 2.96E+00 2.61E-01 1.42E-01 2.34E-01 2.42E-01 1.41E-02 0.00E+00 1.03E+00
STA-NB-10 7.28E-01 1.37E+00 3.05E+00 1.90E-01 1.21E-01 7.30E-03 0.00E+00 2.64E-01
STA-NB-12 5.60E-01 - 7.45E-02 3.49E-01 8.12E-02 0.00E+00 6.47E-02 3.14E-01
STA-NB-3 9.82E-01 2.39E-01 8.67E+00 1.59E+01 4.86E-01 0.00E+00 2.22E-01 7.43E-01
STA-NB-8 2.30E-01 5.44E+00 1.04E+00 6.26E-01 6.99E-02 1.38E-02 9.05E-02 5.20E-01
TR-14 1.61E+00 3.59E-01 4.11E-02 1.63E-01 4.47E-02 0.00E+00 1.75E-02 2.00E-01
UHG-NP 2.09E+00 1.91E-01 6.96E-02 6.09E-01 2.04E-01 4.86E-02 8.88E-02 3.58E-01
Human brain 9.74E-03 2.11E-01 - - - 0.00E+00 5.68E-02 1.16E-01
Human fetal brain - - - - - 6.95E-02 0.00E+00 2.20E-01
Human heart 1.67E-03 1.78E-01 1.20E-01 5.13E-01 5.18E-02 0.00E+00 3.44E-02 3.75E-01
Human kidney 3.53E-02 1.37E-01 9.06E-02 4.21E-01 2.06E-01 3.27E-02 6.82E-02 6.12E-01
Human liver 1.91E-03 1.26E-01 1.20E-01 3.89E-01 1.73E-01 0.00E+00 7.45E-02 5.94E-01
Human lung 6.61E-03 1.94E+00 6.95E-02 3.82E-01 7.77E-01 2.18E-02 1.05E-01 1.10E+00
Human mammery gland - - - - - 4.63E-02 4.10E-02 9.39E-01
Human trachea 1.19E-02 3.81E-01 1.90E-02 2.06E-01 1.11E+00 0.00E+00 6.02E-02 1.09E+00
Human uterus - - - - - 4.34E-02 2.55E-01 6.70E+00Page 7 of 14
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two different regions, of which the 2p24 region appears to
be amplified contiguously, while the other region is
amplified in a discontinuous manner as demonstrated by
the presence of a single copy region on 2p13-14, flanked
on both sides by amplified sequences. The non-synthenic
amplification and inherent fusion of the 2 amplification
sites may have caused the formation of a fusion transcript,
with activation of cryptic exons, which are not transcribed
under normal circumstances. This amplified and highly
expressed fusion transcript contains part of the TEM8 gene
on 2p13.3, fused to anonymous spliced sequences located
in BAC clone RP11-314E10 on band 2p24.3. The occur-
rence of a fusion transcript as a result of amplicon
formation has been described in a breast cancer cell line
MCF7 (caused by non-synthenic co-amplification of two
common amplification sites in breast cancer, i.e. 17q23
and 20q13) [21]. However, the significance of these
fusion transcripts is at present unclear as no similar fusion
transcripts have been detected in other neuroblastoma or
breast cancer cells.
Our study clearly demonstrates the power, speed and effi-
cacy of combined subtractive cDNA cloning and DNA
copy number determination using array CGH for the
identification of clones that are overexpressed and part of
the amplicon, within 4 weeks time. Moreover, the proce-
dure results in the infinite availability of the subtracted
cDNA clones, suitable for downstream analyses, such as
Northern blot, in situ hybridization or RNA interference
using diced double stranded RNA. As a further improve-
ment and simplification of the proposed strategy, we rec-
ommend to sequence only the amplified genes detected
on the array, instead of sequencing all subtracted clones as
performed in this proof-of-principle study. The proposed
strategy will not allow isolation of genes which are
amplified but not overexpressed. However, one can ques-
tion the relevance of these genes, as these will most prob-
ably not have any biological effect. To our knowledge,
such amplification events have not been reported yet.
Oncogene identification consisting of prior selection of
differentially expressed genes has already been reported in
other cancer cell lines, but -unlike our strategy- was
severely hampered by a rate-limiting step for the verifica-
tion of amplification by radiation hybrid mapping of the
subtracted clones [22]. Table 4 summarizes the different
strategies used in the past for the identification of
amplified genes in neuroblastoma cells. Some of these
reports employed a laborious and/or technically challeng-
ing method to identify or clone only one single amplified
gene. In contrast, a recent study provided a global gene
content analysis of the observed amplicons in IMR-32
cells, using CGH on cDNA microarrays [17]. However,
this approach was restricted to the identification of genes
that were present on the microarray and consequently
missed some genes as compared to our strategy (such as
the known amplified DDX1 gene, previously unannotated
NAG exons, the TEM8 gene and fusion transcript). Ampli-
fication of DNMT3A located at 2p23.3, was also reported
in above referenced CGH on cDNA microarray study. As
the subtractive cDNA cloning procedure did not yield a
clone for this gene we performed real-time quantitative
PCR analyses which clearly showed that no DNMT3A
amplification nor overexpression was present in the
investigated IMR-32 cells in this study. An explanation for
this discrepancy may be cell heterogeneity, as it has been
reported that a third amplification site was only present in
a minor portion of IMR-32 cells [10].
Investigation of the amplification status of IMR-32 ampli-
fied genes in other NB cell lines revealed that three of the
nine genes were also amplified in other samples, albeit
always co-amplified with MYCN. However, it remains an
unsolved question whether co-amplified genes represent
silent passengers, or co-determinants of phenotype [23].
The frequently co-amplified gene DDX1 is a nice example,
as no correlation between amplification and patient
outcome could be established [24], but nevertheless, the
gene appears to have oncogenic properties [23]. Six of the
nine identified genes, were only amplified in cell line
FISH based visualisation of MYCN co-amplification with other genes on 2p n neuroblastoma cell line IMR-32igure 3
FISH based visualisation of MYCN co-amplification 
with other genes on 2p in neuroblastoma cell line 
IMR-32: Amplification is present under the form of homoge-
neously staining regions. MYCN (in red) in combination with 
BAC clone RP11-85D18 (TEM8) (in green). Similar results 
(data not shown) were obtained with clone RP11-444B4 
(MEIS1), clone RP11-314E10 (NSE1 and g10d12), clone 
RP11-422A6 (DDX1) and clone RP11-516B14 (NAG).Page 8 of 14
(page number not for citation purposes)
BMC Genomics 2004, 5 http://www.biomedcentral.com/1471-2164/5/11Relative expression levels obtained by real-time quantitative RT-PCRFigure 4
Relative expression levels obtained by real-time quantitative RT-PCR: Relative mRNA expression levels obtained by 
quantitative PCR in 30 neuroblastoma cell lines and 9 normal human tissue samples (samples with gene amplification are 
marked in red) (relative scale, rescaled to an average expression level of 1).
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single sample does not preclude in advance its possible
role in tumour biology. An interesting example is the
MEIS1 oncogene, with proven oncogenic properties
(reviewed in [25]). Albeit amplified in only one neurob-
lastoma sample, the gene is overexpressed in about one
quarter of other tested neuroblastoma tumour samples
([13] and this study). A similar situation occurs for TEM8,
a tumour-specific endothelial marker that has been impli-
cated in colorectal cancer [26]. Besides amplification and
overexpression in IMR-32, high TEM8 expression inde-
pendent of gene amplification is observed, suggesting
alternative pathways for gene activation and a possible
role in neuroblastoma pathogenesis. Further evidence
that one or more genes in the 2p13-14 amplicon plays a
role in neuroblastoma comes from the observation of
genomic amplification at chromosome bands 2p13-14 in
3 primary tumour samples, from a large European multi-
centre CGH study of 204 cases [27]. Unfortunately, no
material was available for further investigation of these
samples. Clearly, more detailed analyses of the amplified
genes (amongst others in a large cohort of uniformly
treated primary tumour samples) and functional studies
are required to establish a possible role of one of the new
genes in tumourigenesis.
Conclusions
The present study shows that the combinatorial method
of subtractive cDNA cloning followed by array CGH
allows straightforward and efficient isolation of overex-
pressed genes located in amplification sites. The validity
of our approach is clearly illustrated by the detection of all
genes that were previously found to be amplified in neu-
roblastoma cell line IMR-32; the identification of 3 newly
amplified genes and a fusion transcript and the generation
of new data on gene content and structure of the
amplicon.
Methods
DNA and RNA isolation
DNA from cultured neuroblastoma cells and 75 MYCN
amplified DNA tumours was extracted using the Easy
DNA kit following the instructions of the manufacturer
(Invitrogen). Total RNA of cultured cell lines was isolated
using the RNeasy Midi kit (Qiagen), and mRNA was
extracted from SK-N-SH and IMR-32 with the FastTrack kit
(Invitrogen), both according to the manufacturer's
instructions.
RNA and DNA concentration was determined using the
Picogreen and Ribogreen reagent, respectively (Molecular
Probes) on a TD-360 fluorometer (Turner Designs).
Suppression subtractive hybridization (SSH)
Starting from 2 µg of mRNA from cell lines SK-N-SH
(driver) and IMR-32 (tester), SSH was performed with the
PCR-Select cDNA Subtraction kit (BD Biosciences, Clon-
tech) as described by the manufacturer. The PCR product
mixture of putative differentially expressed genes was sub-
cloned into the pGEM-T Easy vector (Promega) and prop-
agated in DH5α E. coli. 960 clones were picked, grown in
96-well plates and stored as glycerol stocks at -80°C for
further analysis. Differential screening was performed to
eliminate possible false positive clones according to the
guidelines described in the Differential Screening kit (BD
Biosciences, Clontech).
DNA sequencing and analysis
SSH clones were PCR amplified using SP6 and T7 vector
specific sequences flanking the cloning site. PCR products
were exonuclease and phosphatase treated and cycle
sequenced using BigDyeTerminator chemistry on an
ABI377 (Applied Biosystems) with primers that annealed
to the SP6 or T7 sequences. Similarity searches were per-
formed using the BLAST algorithm [28] after removing
vector and masking repeat sequences using RepeatMasker
[29]. Sequence alignment and EST contig building were
performed using the freely available BioEdit package [30].
Microarray slide production
From selected SSH clones, plasmid DNA was prepared
using the Montage Plasmid Miniprep96 Kit (Millipore)
according to the manufacturer. The plasmid insert was
amplified on a PTC-200 DNA engine (MJ Research) in a
total volume of 100 µl containing 1 µl of 1/100 diluted
plasmid DNA (1–2 ng), 1 × PCR Gold buffer (Applied
Biosystems), 5 mM MgCl2, 400 µmol of each dNTP, 5 U
AmpliTaq Gold DNA polymerase (Applied Biosystems)
and 1 µmol of each primer (amino-linked SP6 and T7
primers). The cycling conditions comprised 5 min
polymerase activation at 95°C, 40 cycles with denatura-
tion at 94°C for 15 sec, annealing at 55°C for 15 sec and
extension at 72°C for 2 min, and a final extension for 5
min at 72°C. PCR products were run on a 1.5% TBE-aga-
rose gel. After vacuum centrifugation, dried PCR products
were dissolved in 20 µl spotting buffer (200 mM sodium
phosphate buffer pH 8.5, 0.2% sarcosyl) and rearrayed in
a 384 well plate. The PCR products were then arrayed in
triplicate on CodeLink Activated Slides (Amersham Bio-
sciences) using a GMS417 spotter (MWG Biotech). After
48 hour incubation in a NaCl humidified chamber, slides
were transferred to 1% ammonium hydroxide solution
for 5 min, rinsed in Milli-Q ddH2O (Millipore) at room
temperature and then placed in 95°C Milli-Q ddH2O for
2 min to completely denature the bound DNA molecules.
After transfer to ice-cold Milli-Q ddH2O, slides were
briefly rinsed twice in room temperature Milli-Q ddH2OPage 10 of 14
(page number not for citation purposes)
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rpm.
CGH on cDNA microarray
This protocol is based on a previously published CGH on
cDNA microarray protocol [31] and a CGH on BAC
microarray protocol [32].
Approximately 10 µg of genomic DNA of neuroblastoma
cell line IMR-32 and a normal male lymphoblastoid cell
line was digested overnight at 37°C with 25 units AluI
and RsaI in 100 µl React1 buffer (Invitrogen). Digested
DNA was purified using QIAquick PCR purification col-
umns (Qiagen) according to the manufacturer.
Purified DNA was labelled using the BioPrime random-
priming labelling kit (Invitrogen) substituting the biotin
labelled nucleotide with Cy3-dCTP and Cy5-dCTP for
tumour and normal DNA, respectively. A total of 4 label-
ling reactions were set up (2 reactions for each Cy dye),
each containing 2 µg of digested DNA. Twenty µl 2.5 ×
random primer buffer mix was added to 2 µg DNA
(diluted in 21 µl) and then boiled for 10 min. On ice, 5 µl
10 × dNTP mix (2 mM each dATP, dGTP, and dTTP and
0.5 mM dCTP in TE), 3 µl Cy5 or Cy3-dCTP (Amersham
Biosciences, 1 mM) and 1 µl Klenow Fragment were
added to each tube. This mixture was incubated at 37°C
for 2 hours and stopped by adding 5 µl stopping buffer.
The DNA probes were purified on a Microspin G50 col-
umn (Amersham Biosciences) as described by the manu-
facturer. Cy3 and Cy5 labelled probes were subsequently
mixed and combined with 50 µg human Cot-1 DNA (Inv-
itrogen), 100 µg yeast tRNA and 20 µg poly dA (Sigma).
After ethanol-sodium acetate precipitation, the probe was
dissolved in 70 µl hybridisation buffer (50% formamide,
10% dextrane sulphate, 0.1% Tween20, 2 × SSC, 10 mM
Tris/HCl pH 7.4). The hybridisation mixture was then
denatured at 100°C for 2 min and incubated for 30 min
at 37°C in a PTC-200 thermocycler (MJ Research). The
probe was applied to a microarray slide that had been pre-
hybridised for 2 hours with hybridisation buffer. An open
hybridisation (without cover slip) was performed for 2
nights at 37°C in a sealed, humidified chamber on a rock-
ing table. Washes were performed in three steps: PBS/
0.05% Tween20 for 10 min at room temperature, 50%
formamide/ 2 × SSC for 30 min at 42°C and PBS/ 0.05%
Tween20 for 10 min at room temperature. Slides were
dried by spinning for 5 min at 500 rpm.
The slides were scanned in a GMS418 scanner (MWG Bio-
tech) and images were analyzed using ImaGene v5.5 soft-
ware (BioDiscovery). After background subtraction, spots
(background signal < signal, for the 2 colours) were nor-
malized with the geometric mean of selected data points
(signal > background signal + 3 × standard deviation of all
background signals, for the 2 colours). Ratios were calcu-
lated using these normalized data and put in a graph
against the base position of the clone according the
human genome browser at UCSC (April 2003 freeze
[33]).
Real-time quantitative PCR based copy number 
determination and gene expression analysis
The gene copy number of known genes MYCN, DDX1,
NAG, MEIS1, TEM8, BPM10, PLEK, PPP3R1 and DNMT3A
and anonymous SSH clones g10e3, g9d9, g10d12, g4d5
and g2h10a was determined in 32 other neuroblastoma
cell lines with listed primers (Table 1) according to a pre-
viously described protocol with BCMA and SDC4 as nor-
malizing control genes and normal human genomic DNA
(Roche) as calibrator sample [24]. Clones that were found
to be amplified in cell lines other than IMR-32 were also
tested in 75 MYCN amplified tumours. PCR reactions
were performed on an ABI 5700 SDS (Applied Biosys-
tems). Amplification mixtures (25 µl) contained template
DNA (approximately 10 ng), 1 × qPCR MasterMix for
SYBR Green I (Eurogentec) and 300 nM of each primer.
The cycling conditions comprised 10 min polymerase
activation at 95°C, 40 cycles at 95°C for 15 sec and 60°C
for 1 min. A dissociation curve was run after each PCR
reaction in order to verify amplification specificity.
The relative expression levels of the clones were deter-
mined in the neuroblastoma cell line panel and on 9 nor-
mal tissue samples (RNA obtained from BD Biosciences,
Clontech) using the above listed primer pairs according to
an optimized two-step real-time SYBR Green I RT-PCR
assay [34]. The gene expression levels were normalized
using the geometric mean of 4 stable housekeeping genes
in neuroblastoma (SDHA, UBC, GAPD and HPRT1) as
described previously [35].
Validation of amplification with FISH
FISH was performed using the LSI MYCN SpectrumOr-
ange probe (Vysis) in combination with BAC clone RP11-
422A6 containing DDX1, BAC clone RP11-516B14
containing NAG, BAC clone RP11-444B4 containing
MEIS1, BAC clone RP11-314E10 containing NSE1 and
SSH clone g10d12 and BAC clone RP11-85D18 contain-
ing TEM8. Labelling and FISH was performed as described
[36].
Further characterization of anonymous SSH clones
RT-PCR assays on IMR-32 cDNA were designed to test
whether an anonymous SSH clone and a neighbouring
(putatively not yet fully annotated) transcript are part of
the same gene. Taking into account the orientation of the
sequences, a forward primer was designed in the SSH
clone and a reverse primer in the known transcript: for-
ward primer in clone g10e3Page 11 of 14
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reverse primer in gene NSE1
5'GGAGGAAGATGGCGCTGCGAATTC3', forward primer
in clone g9d9
5'CCACAGAAGGTGTTTCACACCCAGCCT3' and reverse
primer in NSE1 5'GGAGGAAGATGGCGCTGCGAATTC3';
forward primer in clone g10d12 5'GACAGGCTT-
GCCAATTTTCACAGTGTGG 3' and reverse primer in gene
NSE1 5'CCCGACCCGCAGTTCGTCCTTTT3'; forward
primer in clone g4d5
5'AGCTAGGCTCGCAAACAACGTTTCCAGA3' and
reverse primer in gene ETAA16
5'GCCAAGAACTGCCAGAGGCTTTTTGGA3'. To deter-
mine the NAG transcript length between exon 4 and 7
(acc. no. AF056195), RT-PCR with a forward primer in
exon 4 and a reverse primer in exon 7 was performed (F
5'GCTCCCTGATGGACTGGTTCGCTTGGT3' and R
5'CCGGCCAGTGTGCCTCGTCAATCTA3'). Examination
of the fusion transcript was done with a forward primer in
the first part of the transcript (F
5'CACACTGTTCTGACGGTTCCA3') and a reverse primer
in the other part (R
5'CAAAGTAGAATATAGTTGTCCAAAACACAA3'). RT-
PCR amplification on random hexamer primed IMR-32
cDNA was performed with the Advantage 2 PCR Kit
(Clontech, BD Biosciences) according to the
manufacturer.
PCR fragments run on a 1.5% TBE-agarose gel were
excised and purified on a GenElute Minus EtBr Spin
Column (Sigma-Aldrich). Cycle sequencing was per-
formed using purified amplicons (3–10 ng) using the
above-mentioned primers at a concentration of 80 nM
and the ABI PRISM BigDye Terminators v3.0 Cycle
Sequencing Kit (Applied Biosystems) according to the
manufacturer, with the following thermocycling condi-
tions: 25 cycles at 92° for 10 sec, 55°C for 5 sec and 60°C
for 3.5 min. Sequencing of the fusion transcript was pre-
ceded by cloning of the PCR product with the TOPO TA
cloning kit for sequencing (Invitrogen). After ethanol pre-
cipitation, the products were run on an automated
sequencer ABI3100 and analyzed with the Sequencing
Analysis software v3.7 (Applied Biosystems).
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